Literature DB >> 26301071

hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes.

Jules C Hancox1, Dario Melgari2, Christopher E Dempsey3, Kieran E Brack4, John Mitcheson5, G André Ng6.   

Abstract

Entities:  

Year:  2015        PMID： 26301071      PMCID： PMC4530352          DOI： 10.1177/2042098615595546

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  13 in total

1.  Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction.

Authors:  Giuseppe Cocco; Paul Jerie
Journal:  Cardiovasc Toxicol       Date:  2015-01       Impact factor: 3.231

Review 2.  Novel If current inhibitor ivabradine: safety considerations.

Authors:  Irina Savelieva; A John Camm
Journal:  Adv Cardiol       Date:  2006

3.  Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL.

Authors:  C Ceconi; S B Freedman; J C Tardif; P Hildebrandt; T McDonagh; P Gueret; G Parrinello; M Robertson; P G Steg; M Tendera; I Ford; K Fox; R Ferrari
Journal:  Int J Cardiol       Date:  2010-11-26       Impact factor: 4.164

4.  Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology.

Authors:  A John Camm; Chu-Pak Lau
Journal:  Drugs R D       Date:  2003

5.  Ivabradine in stable coronary artery disease without clinical heart failure.

Authors:  Kim Fox; Ian Ford; Philippe Gabriel Steg; Jean-Claude Tardif; Michal Tendera; Roberto Ferrari
Journal:  N Engl J Med       Date:  2014-08-31       Impact factor: 91.245

Review 6.  Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.

Authors:  Gordon F Rushworth; Philippe Lambrakis; Stephen J Leslie
Journal:  Ther Adv Drug Saf       Date:  2011-02

Review 7.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

8.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

9.  Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials.

Authors:  Ruairidh I R Martin; Oksana Pogoryelova; Mauro Santibáñez Koref; John P Bourke; M Dawn Teare; Bernard D Keavney
Journal:  Heart       Date:  2014-06-20       Impact factor: 5.994

10.  hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.

Authors:  Dario Melgari; Kieran E Brack; Chuan Zhang; Yihong Zhang; Aziza El Harchi; John S Mitcheson; Christopher E Dempsey; G André Ng; Jules C Hancox
Journal:  J Am Heart Assoc       Date:  2015-04-24       Impact factor: 5.501
View more
  2 in total

1.  The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain.

Authors:  Laura Perissinotti; Jiqing Guo; Meruyert Kudaibergenova; James Lees-Miller; Marina Ol'khovich; Angelica Sharapova; German L Perlovich; Daniel A Muruve; Brenda Gerull; Sergei Yu Noskov; Henry J Duff
Journal:  Mol Pharmacol       Date:  2019-06-10       Impact factor: 4.436

2.  Acute on Chronic Ivabradine Overdose: a Case Report.

Authors:  Kevin Maskell; Adele Tse; Carl E Wolf; Michelle Troendle
Journal:  J Med Toxicol       Date:  2016-02-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.